Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bisoprolol + perindopril + indapamide + amlodipine
- Development stage
- Unknown
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bisoprolol + perindopril + indapamide + amlodipine is a quadruple fixed-dose combination (FDC) antihypertensive therapy developed by Servier. It combines four active small-molecule ingredients with complementary mechanisms of action: bisoprolol (a selective beta-1 adrenergic receptor blocker), perindopril (an angiotensin-converting enzyme inhibitor), indapamide (a thiazide-like diuretic), and amlodipine (a dihydropyridine calcium channel blocker). This single-pill combination (SPC) is indicated for the treatment of essential hypertension, particularly in patients whose blood pressure remains uncontrolled on triple therapy. By consolidating four agents into a single daily pill, the therapy aims to simplify complex treatment regimens, reduce pill burden, and improve patient adherence. The combination has been evaluated in clinical trials, including the Phase 3 QUADRO study, which demonstrated its efficacy and safety in achieving blood pressure targets compared to free combinations of the individual components.
- Other names
- bisoprolol/perindopril/indapamide/amlodipineperindopril/indapamide/amlodipine/bisoprololquadruple single-pill combination antihypertensive therapy
02
Targets
ADRB1 (β1)ACE (Angiotensin Converting Enzyme)LTCC (Voltage-gated calcium channel (L-type))ADRB2 (β2)
Beyond the preview
Go deeper on bisoprolol + perindopril + indapamide + amlodipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bisoprolol + perindopril + indapamide + amlodipine.